Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1 2 or 4 weeks

A KiialainenJ I AdamkewiczC PetryJ OldenburgE et alJohnny Mahlangu2024-09-182024-09-18WOS2475-0379https://hdl.handle.net/10539/40941Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1 2 or 4 weeksJournal Article